Publications 2005

Abraham K., Brandenburger L., Meckert C., Ittrich C., Kopp-Schneider A., Krause E., Lamer S., Geusau A., Gundert-Remy U., Oberemm A.: Severe 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) intoxication : search for human serum biomarkers using 2d electrophoresis based proteomic analysis. Naunyn-Schmiedeb.Arch.Pharmacol. 371(Suppl.1), p.R109 (458), 2005.

Andritzky B., Dürk H., Burkholder I., Edler L., Schuch G., Boeters I., Görn M., Popp J., Lipp R., Horst H., Hossfeld D.K., Bokemeyer C., Laack E.: Pilot study of docetaxel and cisplatin as first-line treatment for patients with advanced esophageal cancer. Onkol. 28(S3), p.240 (No.745), 2005.

Benner A.: MFP - multivariable fractional polynomials. R-News 5 (2) 20-23, 2005.

Benner A., Ittrich C., Mansmann U.: Predicting survival using microarray gene expression data. Gesellschaft für Klassifikation , 2005.

Benner A.: Comments on 'Statistical learning from data'. 2005. Bull.Int.Statist.Inst. Proceedings 54th Session Book 2.

Beyer S., Kröger M., Kopp-Schneider A., Ittrich C.: SELDI-TOF: a possible approach to determine carcinogen induced changes in rat liver proteom. Naunyn-Schmiedeb.Arch.Pharmacol. 371(Suppl.1), p.R120 (502), 2005.

Beyer S., Kröger M., Kopp-Schneider A., Ittrich C.: Analysis of SELDI-TOF spectra to determine carcinogen induced changes in rat liver proteom. Internationale Biometrische Gesellschaft 51. Biometrisches Kolloquium, 21. - 23. März 2005, Halle, Germany, p.73, 2005.

Blonski K., Schumacher U., Burkholder I., Edler L., Nikbakht H., Boeters I., Peters A., Kugler C., Horny H.P., Langer M., Wilhelm-Ogunbiyi K., Witthohn K., Laack E.: Binding of the recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung. Anticanc.Res. 25 (5) 3303-3307, 2005.

Bräuning A., Jaworski M., Köhle C., Ittrich C., Stahl S., Buchmann A., Schwarz M.: REX3, a new gene potentially linked to tumor formation in mouse liver. Naunyn-Schmiedeb.Arch.Pharmacol. 371(Suppl.1), p.R115 (483), 2005.

Buchholz E., Thatcher N., Kortsik C., Koschel G., Spengler W., Pilz L., Mezger J., Manegold C.: A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine and docetaxel: second interim study results. Onkol. 28(1), p.55, 2005.

Buckowitz A., Knaebel H.P., Benner A., Bläker H., Gebert J., Kienle P., Knebel-Doeberitz M.v., Kloor M.: Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br.J.Cancer 92 (9) 1746-1753, 2005.

Combs S.E., Gutwein S., Schultz-Ertner D., van Kempen M., Thilmann C., Edler L., Wannenmacher M., Debus J.: Temozolomide combined with radiation as postoperative treatment of primary glioblastoma multiforme: phase I/II study. Strahlenther.Onkol. 181 (6) 372-377, 2005.

Combs S.E., Schultz-Ertner D., Thilmann C., Edler L., Debus J.: Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma. Int.J.Radiat.Oncol.Biol.Phys. 62 (3) 797-802, 2005.

Combs S.E., Thilmann C., Edler L., Debus J., Schultz-Ertner D.: Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J.Clin.Oncol. 23 (34) 8863-8869, 2005.

Cremer F.W., Bouko Y., Samson D., Apperley J.F., Thielemans K., Van Camp B., Benner A., Goldschmidt H., Moos M., Bakkus M.H.: Response to Owen and Rawston. Brit.J.Haematol. 128 (5) 733-734, 2005.

Cremer F.W., Bila J., Buck I., Kartal M., Hose D., Ittrich C., Benner A., Raab M.S., Theil A.C., Moos M., Goldschmidt H., Bartram C.R., Jauch A.: Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes, Chromosomes & Cancer 44 (2) 194-203, 2005.

Cremer F.W., Bila J., Buck I., Kartal M., Hose D., Ittrich C., Benner A., Raab M.S., Moos M., Jauch A., Bartram C.R., Goldschmidt H.: Multiple myeloma: delineation of distinct subgroups and a model for clonal evolution based on interphase fluorescence-in-situ-hybridization. Onkol. 28(S3), p.164 (No.503), 2005.

Dally H., Tüngerthal S., Drings P., Fischer J., Edler L., Jäger B., Schmezer P., Spiegelhalder B., Bartsch H., Risch A.: Association of XRCC-1 genotype with chemotherapy response in lung cancer patients. Naunyn-Schmiedeb.Arch.Pharmacol. 371(Suppl.1), p.R137 (569), 2005.

Dähn S., Schwalbach P., Maksan S., Wöhleke F., Benner A., Kuntz C.: Influence of different gases used for laparoscopy (helium, carbon dioxide, room air, and xenon) on tumor volume, histomorphology, and leukocyte-tumor-endothelium interaction in intravital microscopy. Surg.Endosc. 19 (1) 65-70, 2005.

Deichmann M., Thome M., Benner A., Kirschner M., Hassanzadeh J., Kurzen H.: Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases. BMC Cancer 5 (1) 58, 2005.

Edler L., Benner A., Ittrich C.: On the statistical design of pharmacogenomic clinical studies using predictive information of gene-expression signatures. 2005. Bull.Int.Statist.Inst. Proceedings 54th Session Book 2.

Edler L.: Computational Statistics und Biometrie. Wer treibt wen? Computational statistics and biometry. Which discipline drives which? GMS Med.Inform.Biom.Epidemiol. 1 (2) doc10-(20050620) , 2005.

Edler L., Kopp-Schneider A.: Letter to the editor: Origins of the mutational origin of cancer. Int.J.Epidemiol. 34 (5) 1168-1170, 2005.

Edler L., Burkholder I.: Overview of phase I trials. In: J.C.Crowley, D.P.Ankerst (Eds.), Handbook of statistics in clinical oncology. Chapman & Hall/CRC Press Taylor & Francis, Boca Raton, 2005, pp.3-29.

Edler L., Pilz L.: Klinische Studien. In: C.Manegold (Ed.), Therapieoptionen beim nicht-kleinzelligen Bronchialkarzinom. UNI-MED, Bremen, 2005, pp.178-188.

Edler L., Kopp-Schneider A., Heinzl H.: Dose-response modeling. In: L.Edler, C.P.Kitsos (Eds.), Recent advances in quantitative methods in cancer and human health risk assessment. Wiley, Chichester, West Sussex, UK, 2005, pp.211-237.

Edler L., Kitsos C.P.: Recent advances in quantitative methods in cancer and human health risk assessment. 2005. Chichester, West Sussex, UK, 463p. Wiley Series in Probability and Statistics. Shewhart W. A. & Wilks S. S. (eds) .

Findeisen P., Kloor M., Merx S., Sutter C., Wörner S.M., Dostmann N., Benner A., Dondog B., Pawlita M., Dippold W., Wagner R., Gebert J., v.Knebel-Doeberitz M.: T25 repeat in the 3' untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res. 65 (18) 8072-8078, 2005.

Freyschmidt-Paul P., McElwee K.L., Hoffmann R., Sundberg J.P., Kissling S., Hummel S., Vitacolonna M., Kopp-Schneider A., Zöller M.: Reduced expression of interleukin-2 decreases the frequency of alopecia areata onset in C3H/HeJ mice. J.Invest.Dermatol. 125 (5) 945-951, 2005.

Gerull S., Görner M., Benner A., Hegenbart U., Klein U., Schäfer H., Goldschmidt H., Ho A.D.: Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant. 36 (11) 963-969, 2005.

Gnad-Vogt S.U., Hofheinz R.D., Saussele S., Kreil S., Willer A., Willecke F., Pilz L., Hehlmann R., Hochhaus A.: Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial. Anticancer Drugs 16 (4) 435-440, 2005.

Görn M., Anige M., Burkholder I., Müller B., Scheffler A., Edler L., Boeters I., Panse J., Schuch G., Hossfeld D.K., Laack E.: Serum levels of magic roundabout protein in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 49 (1) 71-76, 2005.

Görn M., Anige M., Burkholder I., Scheffler A., Edler L., Boeters I., Panse J., Schuch G., Hossfeld D.K., Bokemeyer C., Laack E.: Correlation of pre-treatment serum levels of magic roundabout protein with overall survival in patients with advanced non-small cell lung cancer (NSCLC). J.Clin.Oncol. 23(16 (Suppl.)), p.7199, 2005.

Gundert-Remy U., Dahl S.G., Boobis A., Kremers P., Kopp-Schneider A., Oberemm A., Renwick A., Pelkonen O.: Molecular approaches to the identification of biomarkers of exposure and effect - report of an expert meeting organized by COST Action B15. Toxicol.Lett. 156 (2) 227-240, 2005.

Hartung G., Hofheinz R., Dencausse Y., Sturm J., Kopp-Schneider A., Dietrich G., Fackler-Schwalbe I., Bornbusch D., Gonnermann M., Wojatschek C., Lindemann H., Eschenburg H., Jost K., Edler L., Hochhaus A., Queisser U.: Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomised phase III study. Onkol. 28 (6-7) 347-350, 2005.

Heinzl H., Mittlböck M., Edler L.: On the role of ex post uncertainty assessment for risk management. Int.J.Risk Assess.Manag. 5 (2/3/4) 206-215, 2005.

Heuser M., Kopun M., Rittgen W., Granzow C.: Cytotoxicity determination without photochemical artefacts. Cancer Lett. 223 (1) 57-66, 2005.

Hillengass J., Wasser K., Benner A., Delorme S., Zechmann C., Ho A.D., Goldschmidt H., Möhler T.: Bone marrow microcirculation parameter amplitude A of contrast-enhanced dynamic MRI is a prognostic factor for progressive multiple myeloma. Onkol. 28(S3), p.165 (No.505), 2005.

Hoffmann D., Pilz L.: RANDI - Online randomisation for small-scale clinical trials. GMS , 2005.

Hoffmann M., Görögh T., Gottschlich S., Lohrey C., Rittgen W., Ambrosch P., Schwarz E., Kahn T.: Human papillomaviruses in head and neck cancer: 8 year-survival-analysis of 73 patients. Cancer Lett. 218 (2) 199-206, 2005.

Hofheinz R.D., Gnad-Vogt U., Wein A., Saussele S., Kreil S., Pilz L., Hehlmann R., Hochhaus A.: Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. Anticancer Drugs 16 (1) 39-45, 2005.

Hose D., Rossi J.F., Ittrich C., de Vos J., Reme T., Benner A., Mahtouk K., del Val C., Moreaux J., Hotz-Wagenblatt A., Jonnakut S., Raab M., Kaukel P., Moos M., Grau V., Jauch A., Jourdan E., Goldschmidt H., Klein B., Cremer F.W.: Molecular classification of multiple myeloma by gene expression profiling and fluorescence in situ hybridisation delineates four groups predictive for event free survival. Onkol. 28(S3), p.164 (No.502), 2005.

Hose D., Rossi J.F., Ittrich C., de Vos J., Reme T., Benner A., Mahtouk K., del Val C., Moreaux J., Hotz-Wagenblatt A., Jonnakut S., Raab M., Kaukel P., Moos M., Grau V., Jauch A., Jourdan E., Cremer F.W., Klein B., Goldschmidt H.: Molecular classification of multiple myeloma (MM) based on gene expression profiling (GEP) and fluorescence in situ hybridisation (FISH) is an independent predictor for event free survival (EFS). Blood 106(11), p.507(Abstr.No.), 2005.

Hussong R., Frank N., Knauft J., Ittrich C., Owen R., Becker H., Gerhäuser C.: A safety study of oral xanthohumol administration and its influence on fertility in Sprague Dawley rats. Mol.Nutr.Food Res. 49 (9) 861-867, 2005.

Ittrich C., Oberemm A., Herzig A., Richter-Reichhelm H.B., Gundert-Remy U., Kalenberg K., Krause E., Kröger M., Fella K., Hellmann J., Kramer P.J., Glückmann M., Ellinger-Ziegelbauer H., Ahr H.J., Scholz G., Kiss E., Kopp-Schneider A.: Correlation of n-nitrosomorpholine induced changes in rat liver transcriptome and proteome. Naunyn-Schmiedeb.Arch.Pharmacol. 371(Suppl.1), p.R120 (500), 2005.

Ittrich C., Benner A., Edler L., Schimek M.G.: Statistical learning for analyzing functional genomic data. 2005. Bull.Int.Statist.Inst. Proceedings 54th Session Book 2.

Ittrich C., Richter W.D.: Exact tests and confidence regions in nonlinear regression. Statistics 39 (1) 13-42, 2005.

Ittrich C.: Normalization for two-channel microarray data. Meth.Inf.Med. 44 (3) 418-422, 2005.

Jaworski M., Hailfinger S., Buchmann A., Hergenhahn M., Hollstein M., Ittrich C., Schwarz M.: Human p53 knock-in (HUPKI) mice do not differ in liver tumor response from their counterparts with murine p53. Carcinogen. 26 (10) 1829-1834, 2005.

Kienle D., Saupe D., Katzenberger T., Benner A., Rosenwald A., Ott G., Lichter P., Döhner H., Stilgenbauer S.: Quantitative gene expression analysis in mantle cell lymphoma: correlation with clinical and biological factors. Onkol. 28(S3), p.154 (No.472), 2005.

Kienle D., Kröber A., Winkler D., Benner A., Lichter P., Döhner H., Stilgenbauer S.: Quantitative gene expression analysis of surrogate markers for genetic risk groups in CLL. Onkol. 28(S3), p.83 (No.243), 2005.

Kienle D.L., Korz C., Hosch B., Benner A., Mertens D., Habermann A., Kröber A., Jäger U., Lichter P., Döhner H., Stilgenbauer S.: Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J.Clin.Oncol. 23 (16) 3780-3792, 2005.

Kienle P., Z'graggen K., Schmidt J., Benner A., Weitz J., Büchler M.W.: Laparascopic restorative proctocolectomy. Br.J.Surg. 92 (1) 88-93, 2005.

Kirschner M., Helmke B., Starz H., Benner A., Thome M., Deichmann M.: Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases. Melanoma Res. 15 (5) 427-434, 2005.

Kitsos C.P., Edler L.: Cancer risk assessment for mixtures. In: L.Edler, C.P.Kitsos (Eds.), Recent advances in quantitative methods in cancer and human health risk assessment. Wiley, Chichester, West Sussex, UK, 2005, pp.283-298.

Klauck S.M., Felder B., Schuster C., Beyer K.S., Benner A., Poustka F., Poustka A.: Association studies and mutation screening in the German sample of patients with autism spectrum disorders. Am.J.Med.Genet.B Neuropsychiatr.Genet. 138(1), pp.67-68, 2005.

Kloor M., Becker C., Benner A., Wörner S.M., Gebert J., Ferrone S., Knebel-Doeberitz M.v.: Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res. 65 (14) 6418-6424, 2005.

Knaebel H.P., Koch M., Feise T., Benner A., Kienle P.: Diagnostics of rectal cancer: endorectal ultrasound. Recent Results Cancer Res. 165 46-57, 2005.

Kopp-Schneider A., Burkholder I., Groos J.: Stochastic carcinogenesis models. In: L.Edler, C.P.Kitsos (Eds.), Recent advances in quantitative methods in cancer and human health risk assessment. Wiley, Chichester, West Sussex, UK, 2005, pp.125-135.

Kröber A., Bloedorn J., Hafner S., Bühler A., Seiler T., Kienle D., Winkler D., Bangerter M., Schlenk R.F., Benner A., Lichter P., Döhner H., Stilgenbauer S.: Additional genetic high-risk-features define discordance of ZAP-70 an VH mutation status in chronic lymphocytic leukemia. Onkol. 28(S3), p.82 (No.242), 2005.

Küppers M., Ittrich C., Dietrich G.: Expression profiling of contact-inhibition. Naunyn-Schmiedeb.Arch.Pharmacol. 371(Suppl.1), p.R115 (482), 2005.

Laack E., Andritzky B., Dürk H., Burkholder I., Edler L., Schuch G., Boeters I., Görn M., Lipp R., Horst H., Popp J., Hossfeld D.K.: Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal caner: a pilot study. Onkol. 28 647-650, 2005.

Laack E., Scheffler A., Burkholder I., Boeters I., Andritzky B., Schuch G., Görn M., Vohwinkel G., Edler L., Fiedler W., Hossfeld D.K.: Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 50 (1) 51-58, 2005.

Laack E., Boeters I., Krüll A., Engel-Riedel W., Müller T., Meißner R., Dürk H., Lorenz C., Fischer J.R., Gosse H., Kortsik C., Elbers M., Schuch G., Görn M., Andritzky B., Burkholder I., Edler L., Hossfeld D.K., Bokemeyer C.: A phase II study of carboplatin and irinotecan (CPT-11) in patients with limited disease small cell lung cancer (SCLC). Onkol. 28(S3), p.137 (No.411), 2005.

Liebisch P., Scheck D., Erne S.A., Wellmann A., Wendl C., Janczik S., Kolmus S., Krober A., Einsele H., Straka C., Goldschmidt H., Benner A., Stilgenbauer S., Döhner H.: Duplication of chromosome arms 9q and 11q: evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myeloma. Genes, Chromosomes & Cancer 42 (1) 78-81, 2005.

Liebisch P., Benner A., Wendl C., Tschajka K., Goldschmidt H., Döhner H.: Gains on chromosome arm 9q represent a novel and independent marker of adverse prognosis in multiple myeloma patients receiving upfront high-dose chemotherapy and autologous stem cell transplantation. Onkol. 28(S3), p.15 (No.39), 2005.

Manegold C., Pilz L., Koschel G., Schott-von Römer K., Mezger J., Hruska D., Dornoff W., Gosse H., Gatzemeier U.: Randomized multicenter phase II study of gemcitabine versus docetaxel as first-line therapy with second-line crossover in advanced non-small cell lung cancer (GemTax I). Clin.Lung Cancer 7 (3) 208-214, 2005.

Manegold C., Thatcher N., Kortsik C., Koschel G., Spengler W., Mezger J., Müller A., Pilz L.: Sequential versus concomitant administration of docetaxel and gemcitabine as first-line treatment of advanced non-small cell lung cancer (NSCLC): Results of a phase II/III randomised study. Europ.J.Cancer Supplements 3(2), p.326 (Abstr.No.1129), 2005.

Manegold C., Thatcher N., Kortsik C., Koschel G., Spengler W., Mezger J., Müller A., Pilz L.: A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine (G) and docetaxel (D): Update on quality of life (QoL), toxicity, and costs. J.Clin.Oncol. 23(16 (Suppl.)), p.634s (Abstr.No.7057), 2005.

Manegold C., Thatcher N., Kortsik C., Koschel G., Spengler W., Mezger J., Müller A., Pilz L.: Gemcitabine and docetaxel as concomitant or sequential first-line therapy of advanced non-small cell lung cancer: updated results of a randomized study. 11th World Conference on Lung Cancer (WCLC), 3 - 6 July 2005, Barcelona, Spain. Oral Presentation, 2005.

Mendrzyk F., Radlwimmer B., Joos S., Kokocinski F., Benner A., Stange D.E., Neben K., Fiegler H., Carter N.P., Reifenberger G., Korshunov A., Lichter P.: Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J.Clin.Oncol. 23 (34) 8853-8862, 2005.

Michaelovsky E., Frisch A., Leor S., Stein D., Danziger Y., Carel C., Fennig S., Mimouni M., Klauck S.M., Benner A., Poustka A., Apter A., Weizman A.: Haplotype analysis of the COMT-ARVCF gene region in Israeli anorexia nervosa family trios. Am.J.Med.Genet.B Neuropsychiatr.Genet. 139 (1) 45-50, 2005.

Oberemm A., Meckert C., Brandenburger L., Herzig A., Lindner Y., Kalenberg K., Krause E., Ittrich C., Kopp-Schneider A., Stahlmann R., Richter-Reichhelm H.B., Gundert-Remy U.: Differential signatures of protein expression in marmoset liver and thymus induced by single-dose TCDD treatment. Toxicol. 206 (1) 33-48, 2005.

Oberemm A., Richter-Reichhelm H.B., Gundert-Remy U., Tenz K., Krause E., Kröger M., Fella K., Hellmann J., Kramer P.J., Scholz G., Ellinger-Ziegelbauer H., Ahr H.J., Kiss E., Ittrich C., Kopp-Schneider A.: Comparison of histological and toxicogenomic quantification of GST-P in liver of NNM-treated rats. Toxicol.Lett. 158 (Suppl.), p.S70-S71 (P-316), 2005.

Raab M.S., Cremer F.W., Breitkreutz I.N., Gerull S., Luft T., Benner A., Görner M., Ho A.D., Goldschmidt H., Moos M.: Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogenic stem cell transplantation in multiple myeloma. Ann.Oncol. 16 (4) 611-617, 2005.

Rashid M.U., Jakubowska A., Justenhoven C., Harth V., Pesch B., Baisch C., Pierl C.B., Bruning T., Ko Y., Benner A., Wichmann H.E., Brauch H., Hamann U.: German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. Europ.J.Cancer 41 (18) 2896-2903, 2005.

Risch A., Dally H., Tüngerthal S., Drings P., Fischer J., Edler L., Jäger B., Schmezer P., Spiegelhalder B., Bartsch H.: The MPO-129A allele increases the risk of being non-responder in lung cancer chemotherapy. Naunyn-Schmiedeb.Arch.Pharmacol. 371(Suppl.1), p.R134-R135 (560), 2005.

Risch A., Dally H., Edler L.: Genetic polymorphisms in metabolising enzymes as lung cancer risk factors. In: L.Edler, C.P.Kitsos (Eds.), Recent advances in quantitative methods in cancer and human health risk assessment. Wiley, Chichester, West Sussex, UK, 2005, pp.43-62.

Rogers M.A., Edler L., Winter H., Langbein L., Beckmann I., Schweizer J.: Characterization of new members of the human type II keratin gene family and a general evaluation of the keratin gene domain on chromosome 12q13.13. J.Invest.Dermatol. 124 (3) 536-544, 2005.

Rost D., Kopplow K., Gehrke S., Müller S., Friess H., Ittrich C., Mayer D., Stiehl A.: Gender-specific expression of liver organic anion transporters in rat. Eur.J.Clin.Invest. 35 (10) 635-643, 2005.

Schadendorf D., Nestle F.O., Bröcker E.B., Enk A., Grabbe S., Ugurel S., Edler L., Schuler G.: Dacarbacine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) as first-line treatment of patients with metastatic melanoma: Results of a prospective-randomized phase III study. J.Clin.Oncol. 22 (14 (Suppl.)) 7508, 2005.

Schlenk R.F., Germing U., Hartmann F., Glasmacher A., Fischer J.T., del Valle y Fuentes F., Götze K., Pralle H., Nerl C., Salwender H., Grimminger W., Petzer A., Hensel M., Benner A., Zick L., Döhner K., Fröhling S., Döhner H., AML Study Group: High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukem. 19 (6) 978-983, 2005.

Schlingemann J., Habtemichael N., Ittrich C., Toedt G., Kramer H., Hambek M., Knecht R., Lichter P., Stauber R., Hahn M.: Patient-based cross-platform comparison of oligonucleotide microarray expression profiles. Lab.Invest. 85 (8) 1024-1039, 2005.

Schlingemann J., Thuerigen O., Ittrich C., Toedt G., Kramer H., Hahn M., Lichter P.: Effective transcriptome amplification for expression profiling on sense-oriented oligonucleotide microarrays. Nucl.Acids Res. 33 (3) e29, 2005.

Schneeweiss A., Thuerigen O., Toedt G., Warnat P., Hahn M., Rudlowski C., Benner A., Brors B., Sphn C., Lichter P.: Gene expression profiles predict pathologic complete response to preoperative chemotherapy with gemcitabine, epirubicin and docetaxel in primary breast. J.Clin.Oncol. 23(16 (Suppl.)), p.135S, 2005.

Schönberg S.O., Rieger J., Weber C.H., Michaely H.J., Waggershauser T., Ittrich C., Dietrich O., Reiser M.F.: High-spatial-resolution MR angiography of renal arteries with integrated parallel acquisitions: comparison with digital subtraction angiography and US. Radiology 235 687-698, 2005.

Schuster C., Felder B., Klauck S.M., Gohlke H., Illig T., Becker T., Benner A., Poustka F., Poustka A.: Haplotype analysis and association studies in autism candidate genes. Am.J.Med.Genet.B Neuropsychiatr.Genet. 138(1), p.70, 2005.

Stahl S., Ittrich C., Marx-Stölting P., Köhle C., Ott T., Buchmann A., Schwarz M.: Effect of the tumor promotor phenobarbital on the pattern of global gene expression in liver of connexin32-wildtype and connexin32-deficient mice. Int.J.Cancer 115 (6) 861-869, 2005.

Stahl S., Ittrich C., Marx-Stölting P., Köhle C., Altug-Teber Ö., Riess O., Bonin M., Jobst J., Kaiser S., Buchmann A., Schwarz M.: Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatol. 42 (2) 353-361, 2005.

Thatcher N., Manegold C., Kortsik C., Koschel G., Spengler W., Mezger J., Müller A., Pilz L.: Concomitant versus sequential gemcitabine (G) and docetaxel (D) as first-line chemotherapy in advanced non-smallcell lung cancer (NSCLC): updated outcomes and quality of life (QoL) results of a phase II/III randomised study . Ann.Oncol. 16(Suppl.2), p.ii302 (Abstr.No.1320), 2005.

Ugurel S., Bell N., Sucker A., Zimpfer A., Rittgen W., Schadendorf D.: Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int.J.Cancer 117 (5) 825-830, 2005.

Ugurel S., Hildenbrand R., Zimpfer A., La Rosee P., Paschka P., Sucker A., Keikavoussi P., Becker J.C., Rittgen W., Hochhaus A., Schadendorf D.: Lack of clinical efficacy of imatinib in metastatic melanoma. Br.J.Cancer 92 (8) 1398-1405, 2005.

Witzens-Harig M., Hensel M., Schmier J.W., Neben K., Benner A., Krämer A., Ho A.D.: Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin's-lymphoma: First interim results of a prospective randomised phase II study. J.Clin.Oncol. 23(16 (Suppl.)), p.614S, 2005.

Witzens-Harig M., Hensel M., Schmier J.W., Neben K., Benner A., Dreger P., Krämer A., Ho A.D.: Rituximab maintenance therapy in CD20+ B-cell non-Hodgkin-lymphoma. First interim results of a prospective randomised phase II study. Onkol. 28(S3), p.95 (No.282), 2005.

Zorin A., Hanin L., Yakovlev A.Y., Edler L.: Estimating the natural history of breast cancer from bivariate data on age and tumor size at diagnosis. In: L.Edler, C.P.Kitsos (Eds.), Recent advances in quantitative methods in cancer and human health risk assessment. Wiley, Chichester, West Sussex, UK, 2005, pp.317-327.

to top